Low-moisture levamlodipine besylate composition and preparation method thereof

By reducing the moisture content of the levamlodipine benzenesulfonate preparation and using drying treatment, the instability problem under high temperature and high humidity conditions is solved, and long-term storage stability is improved under 30°C.

CN119055647APending Publication Date: 2024-12-03江苏济茗医药有限公司
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202310623045.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-30
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing levamlodipine benzenesulfonate tablets have poor stability, especially in high temperature and high humidity conditions, and the preparation process is complicated, resulting in limited storage conditions.

Method used

By reducing the moisture content of the formulation, a low-moisture lemudipine benzenesulfonate composition, including lemudipine benzenesulfonate, anhydrous calcium hydrogen phosphate, microcrystalline cellulose, disintegrant and lubricant, is used to use a drying box Or dry the coating machine to control the moisture below 1.5% to improve the stability of the preparation.

Benefits of technology

It significantly improves the stability of levamlodipine benzenesulfonate preparation under high temperature and high humidity conditions, so that the storage temperature can be increased to 30°C, and reduces the formation of impurities and unknown monomers, significantly improving the long-term storage stability of the preparation .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004255977270000061
    Figure BDA0004255977270000061
  • Figure BDA0004255977270000062
    Figure BDA0004255977270000062
  • Figure BDA0004255977270000063
    Figure BDA0004255977270000063
Patent Text Reader

Abstract

The invention belongs to the field of medicine preparation, and relates to a low-moisture levamlodipine besylate composition and a preparation method thereof, and the composition comprises the following components: 2-10 wt% of levamlodipine besylate or its hydrate; the content of anhydrous calcium hydrogen phosphate is 10-30 wt%; the content of microcrystalline cellulose is 30-80 wt%; 1-5wt% of a disintegrating agent; and the content of the lubricant is 0.1-5 wt%. According to the method disclosed by the invention, the stability of the levamlodipine besylate preparation under high-temperature and high-humidity conditions is remarkably improved by optimizing and adjusting the drying step.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medicine preparation and relates to a low-moisture levamlodipine besylate composition and a preparation method thereof. Background Art

[0002] Amlodipine besylate tablets were developed by Pfizer, USA, and entered the Chinese market in 1994 under the trade name "Norvasc", a drug for the treatment of hypertension and angina pectoris. Amlodipine is a racemate composed of levoamlodipine and dextroamlodipine, and the calcium ion antagonist activity of the levoamlodipine is 1000 times that of the dextroamlodipine, which is twice that of the racemate, and has less side effects. Therefore, there is a method of splitting amlodipine in the prior art to obtain levoamlodipine. Levoamlodipine besylate has many unique properties and is different from other calcium antagonists, showing long-acting, slow absorption, and gradually producing vasodilation effects. It has a long time of action for lowering blood pressure and anti-angina pectoris, and can be taken once a day, and the action time can be maintained for nearly 24 hours. The side effects are relatively mild, and patients can generally tolerate it, so it is more and more widely used in clinical practice.

[0003] It is worth noting that levamlodipine besylate is hygroscopic, less stable than amlodipine besylate, and less stable to light, moisture, heat, and acid. The preparation process of the levamlodipine besylate tablets currently on the market is complex and has poor stability, so the storage conditions of the commercially available drug instructions are to store in a cool place (not exceeding 20°C). Studies have shown that levamlodipine besylate has good stability under simple high humidity conditions, and there is no obvious change in related substances, but it is extremely unstable under conditions of high temperature and high humidity, and the related substances increase significantly. And the higher the water content of the preparation itself, the more unstable it is under high temperature and accelerated conditions. Light exposure can be solved by using light-proof packaging, and instability to acid can be solved by using the alkaline excipient anhydrous calcium hydrogen phosphate in the prescription, but instability to moisture and heat must be solved from the prescription process itself. Summary of the invention

[0004] In order to solve the above technical problems, the present invention provides a low-moisture levamlodipine besylate composition and a preparation method thereof.

[0005] The technical solution provided by the present invention is as follows:

[0006] A low-moisture levamlodipine besylate composition, which comprises the following components by percentage of the total weight of the composition:

[0007] 2-10 wt % of levamlodipine besylate or its hydrate;

[0008] Anhydrous calcium hydrogen phosphate is 10 to 30 wt%;

[0009] Microcrystalline cellulose is 30-80wt%;

[0010] Disintegrant is 1 to 5 wt%;

[0011] The lubricant is 0.1 to 5 wt%.

[0012] Furthermore, the disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, crospovidone, and low-substituted hydroxypropyl cellulose.

[0013] Furthermore, the lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate.

[0014] Furthermore, the moisture content of the preparation is controlled below 1.5%.

[0015] The present invention also provides a method for preparing a low-moisture levamlodipine besylate composition, comprising the following steps:

[0016] Levoamlodipine sulfonate or its hydrate and anhydrous calcium hydrogen phosphate are sieved, and then evenly mixed with microcrystalline cellulose, a disintegrant and a lubricant, and then tabletted. The obtained tablets are dried and then packaged; the drying method is one or more of air drying oven drying, reduced pressure drying and coating machine drying.

[0017] Furthermore, the drying in the air drying oven is to place the tablets in an air drying oven and dry them at 40-50° C. for 1 to 4 hours.

[0018] Furthermore, the reduced pressure drying is to place the tablets in a vacuum drying oven, evacuate the oven, and dry at 40° C.-50° C. for 1 to 4 hours.

[0019] Furthermore, the coating machine drying is to place the tablets in the coating machine, with an air inlet temperature of 40-50°C, a tablet bed temperature of 40-45°C, and dry for 1 to 4 hours.

[0020] Furthermore, the mixing is performed by using a mixer with a rotation speed of 10 to 20 rpm.

[0021] Furthermore, the packaging material is polyvinyl chloride / polyvinylidene chloride solid medicinal hard tablet and medicinal aluminum foil.

[0022] Beneficial Effects

[0023] The present invention has found in research that by reducing the water content of the levamlodipine besylate preparation itself and controlling the water content below 1.5%, the stability of the preparation can be significantly improved, and the storage temperature of the preparation can be increased to 30° C. The method of the present invention significantly improves the stability of the levamlodipine besylate preparation under high temperature and high humidity conditions by optimizing and adjusting the drying step. DETAILED DESCRIPTION

[0024] Comparative Example 1: (tablets not dried)

[0025] name Single dose prescription / mg 1000 tablets prescription / g effect Levaline besylate 3.47 3.47 Active ingredients Anhydrous calcium hydrogen phosphate 30.0 30.0 Thinner Microcrystalline Cellulose 63.53 63.53 Thinner Sodium starch glycolate 2.0 2.0 Disintegrants Magnesium Stearate 1.0 1.0 Lubricants

[0026] Comparative Example 1 Operation Method:

[0027] (1) Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside;

[0028] (2) Sieving: Pass levoamlodipine besylate and anhydrous calcium hydrogen phosphate through a 60-mesh sieve twice;

[0029] (3) Mixing: Add the sieved material into a mixer, then add microcrystalline cellulose, sodium starch glycolate, and magnesium stearate, and mix at 15 rpm for 10 min to obtain an intermediate.

[0030] (4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting.

[0031] (5) Inner packaging: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid pharmaceutical hard tablets (milky white) and pharmaceutical aluminum foil.

[0032] Comparative Example 2: (Using low-moisture microcrystalline cellulose, the tablets are not dried)

[0033] name Single dose prescription / mg 1000 tablets prescription / g effect Levaline besylate 3.47 3.47 Active ingredients Anhydrous calcium hydrogen phosphate 30.0 30.0 Thinner Microcrystalline cellulose (low moisture) 63.53 63.53 Thinner Sodium starch glycolate 2.0 2.0 Disintegrants Magnesium Stearate 1.0 1.0 Lubricants

[0034] Comparative Example 2 Operation method: Ambient humidity is controlled below 30% RH

[0035] (1) Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside;

[0036] (2) Sieving: Pass levoamlodipine besylate and anhydrous calcium hydrogen phosphate through a 60-mesh sieve twice;

[0037] (3) Mixing: Add the sieved material into a mixer, then add microcrystalline cellulose (low moisture), sodium carboxymethyl starch, and magnesium stearate, and mix at 15 rpm for 10 min to obtain an intermediate.

[0038] (4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting.

[0039] (5) Inner packaging: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid pharmaceutical hard tablets (milky white) and pharmaceutical aluminum foil.

[0040] Example 1: (Tablets are dried in an air drying oven)

[0041] name Single dose prescription / mg 1000 tablets prescription / g effect Levaline besylate 3.47 3.47 Active ingredients Anhydrous calcium hydrogen phosphate 30.0 30.0 Thinner Microcrystalline Cellulose 63.53 63.53 Thinner Sodium starch glycolate 2.0 2.0 Disintegrants Magnesium Stearate 1.0 1.0 Lubricants

[0042] Example 1 Operation method:

[0043] (1) Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside;

[0044] (2) Sieving: Pass levoamlodipine besylate and anhydrous calcium hydrogen phosphate through a 60-mesh sieve twice;

[0045] (3) Mixing: Add the sieved material into a mixer, then add microcrystalline cellulose, sodium starch glycolate, and magnesium stearate, and mix at 15 rpm for 10 min to obtain an intermediate;

[0046] (4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting.

[0047] (5) Drying: Place the tablets in a forced air drying oven at 45°C for 3 h, and control the moisture content of the tablets to below 1.5%;

[0048] (6) Inner packaging: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid pharmaceutical hard tablets (milky white) and pharmaceutical aluminum foil.

[0049] Example 2: (Tablets were dried in a vacuum oven)

[0050] name Single dose prescription / mg 1000 tablets prescription / g effect Levaline besylate 3.47 3.47 Active ingredients Anhydrous calcium hydrogen phosphate 30.0 30.0 Thinner Microcrystalline Cellulose 63.53 63.53 Thinner Sodium starch glycolate 2.0 2.0 Disintegrants Magnesium Stearate 1.0 1.0 Lubricants

[0051] Example 2 Operation method:

[0052] (1) Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside;

[0053] (2) Sieving: Pass levoamlodipine besylate and anhydrous calcium hydrogen phosphate through a 60-mesh sieve twice;

[0054] (3) Mixing: Add the sieved material into a mixer, then add microcrystalline cellulose, sodium starch glycolate, and magnesium stearate, and mix at 15 rpm for 10 min to obtain an intermediate;

[0055] (4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting.

[0056] (5) Drying: Place the tablets in a vacuum drying oven, evacuate the air, and dry at 45°C for 2 h to control the moisture content of the tablets to less than 1.5%;

[0057] (6) Inner packaging: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid pharmaceutical hard tablets (milky white) and pharmaceutical aluminum foil.

[0058] Example 3: (Tablets are dried using a coating machine)

[0059] name Single dose prescription / mg 1000 tablets prescription / g effect Levaline besylate 3.47 3.47 Active ingredients Anhydrous calcium hydrogen phosphate 30.0 30.0 Thinner Microcrystalline Cellulose 632.53 63.53 Thinner Sodium starch glycolate 2.0 2.0 Disintegrants Magnesium Stearate 1.0 1.0 Lubricants

[0060] Example 3 Operation method:

[0061] (1) Weighing: Accurately weigh the raw and auxiliary materials in the prescription and set aside;

[0062] (2) Sieving: Pass levoamlodipine besylate and anhydrous calcium hydrogen phosphate through a 60-mesh sieve twice;

[0063] (3) Mixing: Add the sieved material into a mixer, then add microcrystalline cellulose, sodium starch glycolate, and magnesium stearate, and mix at 15 rpm for 10 min to obtain an intermediate;

[0064] (4) Tableting: Calculate the standard tablet weight based on the intermediate content, and control the tablet weight difference within ±3% for tableting.

[0065] (5) Drying: Place the tablets in a coating machine with an air inlet temperature of 45-50°C and a tablet bed temperature of 40-45°C for 2 hours, and control the moisture content of the tablets to be below 1.5%;

[0066] (6) Inner packaging: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid pharmaceutical hard tablets (milky white) and pharmaceutical aluminum foil.

[0067] Results Discussion and Analysis

[0068] Tablet content and moisture results: As shown in the following table, the moisture content of the tablets of Comparative Example 1 and Comparative Example 2 is 3.41% and 2.64% respectively, and the moisture content of the tablets of Examples 1, 2, and 3 is all below 1.5%. Comparative Example 2, in order to obtain low-moisture tablets, consider using low-moisture excipients. The main free water in the prescription comes from microcrystalline cellulose, which accounts for the largest proportion, with a moisture content of 3%-5%. The moisture content of anhydrous calcium hydrogen phosphate itself is very low (less than 0.5%), and the proportion of disintegrants and lubricants is very small, so the moisture effect of themselves is not considered. Replace the microcrystalline cellulose, which accounts for the largest proportion in the prescription, with a low-moisture model (moisture content is less than 0.5%). Low-moisture microcrystalline cellulose has strong hygroscopicity, and the amlodipine besylate raw material also has hygroscopicity. During the preparation process, even if the ambient humidity is controlled below 30% RH, the moisture content of the final tablet still increases to 2.64%. It shows that it is difficult to effectively reduce the moisture content of the tablet by reducing the initial moisture content of the excipients, and the requirements for ambient humidity are very strict, which increases the difficulty of production.

[0069]

[0070] Stability results of related substances under accelerated (40°C, 75% RH) and long-term (30°C, 60% RH) conditions: (less than 0.01 is considered undetectable, impurity D limit is 1.0, maximum unknown single impurity limit is 0.2, and total impurity limit is 1.5).

[0071]

[0072]

[0073]

[0074]

[0075]

[0076] The above results of related substances show that in Comparative Example 1, the moisture content of the tablets is 3.41%. Under accelerated long-term conditions, impurity D and the maximum unknown single impurity increase significantly. After accelerated 6 months and long-term 24 months, the impurity D is 0.95 and 0.91 respectively, which is at risk of exceeding the limit; the maximum unknown single impurity is 0.25 and 0.31 respectively, which has exceeded the limit by 0.2, and the total impurity is also close to the limit. In Comparative Example 2, by using low-moisture microcrystalline cellulose (moisture content less than 0.5%) and controlling the ambient humidity (less than 30% RH), the tablet moisture content is 2.64%, which has been improved, but the maximum unknown single impurity is still at risk of exceeding the limit after accelerated 6 months and long-term 24 months. In Examples 1, 2, and 3, the tablets are dried in different ways, and the moisture content of the tablets is less than 1.5%. Under accelerated and long-term conditions, compared with Comparative Examples 1 and 2, the increase of impurity D and the maximum unknown single impurity is not obvious, and the total impurity is also significantly reduced. The impurity D is accelerated for 6 months and long-term for 24 months, which is less than 0.5, the maximum unknown single impurity is less than 0.15, and the total impurity is less than 0.5. It can be concluded that drying tablets is significantly easier to operate than controlling the moisture content of excipients and strict environmental humidity, with lower production costs, better control of tablet moisture, and significantly improved stability of related substances in the preparation, allowing tablets to be stored for a long time at 30°C.

Claims

1. A low-moisture levamlodipine besylate composition, characterized in that: The composition comprises the following components by weight: 2-10 wt % of levamlodipine besylate or its hydrate; Anhydrous calcium hydrogen phosphate is 10 to 30 wt%; Microcrystalline cellulose is 30-80wt%; Disintegrant is 1 to 5 wt%; The lubricant is 0.1 to 5 wt%.

2. The low-moisture levamlodipine besylate composition according to claim 1, characterized in that: The disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch, crospovidone, and low-substituted hydroxypropyl cellulose.

3. The low-moisture levamlodipine besylate composition according to claim 1, characterized in that: The lubricant is selected from one or more of magnesium stearate, calcium stearate, stearic acid, and sodium stearyl fumarate.

4. The low-moisture levamlodipine besylate composition according to claim 1, characterized in that: The moisture content of the preparation is controlled below 1.5%.

5. The method for preparing the low-moisture levamlodipine besylate composition according to any one of claims 1 to 4, characterized in that: The following steps are involved: Levoamlodipine sulfonate or its hydrate and anhydrous calcium hydrogen phosphate are sieved, and then evenly mixed with microcrystalline cellulose, a disintegrant and a lubricant, and then tabletted. The obtained tablets are dried and then packaged; the drying method is one or more of air drying oven drying, reduced pressure drying and coating machine drying.

6. The method for preparing the low-moisture levamlodipine besylate composition according to claim 5, characterized in that: The blast drying oven drying is to place the tablets in a blast drying oven and dry them at 40-50° C. for 1 to 4 hours.

7. The method for preparing the low-moisture levamlodipine besylate composition according to claim 5, characterized in that: The reduced pressure drying is to place the tablets in a vacuum drying oven, evacuate the oven, and dry at 40-50° C. for 1 to 4 hours.

8. The method for preparing the low-moisture levamlodipine besylate composition according to claim 5, characterized in that: The coating machine drying is to place the tablets in the coating machine, with an air inlet temperature of 45-50° C., a tablet bed temperature of 40-45° C., and dry for 1 to 4 hours.

9. The method for preparing the low-moisture levamlodipine besylate composition according to claim 5, characterized in that: The mixing is performed by using a mixer with a rotation speed of 10 to 20 rpm.

10. The method for preparing the low-moisture levamlodipine besylate composition according to claim 5, characterized in that: The packaging materials are polyvinyl chloride / polyvinylidene chloride solid medicinal hard tablets and medicinal aluminum foil.

Citation Information

Cited By

  • S-adenosine-L-methionine p-toluenesulfonic acid sulfate composition, coating preparation and preparation method thereof

    CN120037252A